WO2015119575A3 - Procédé amélioré, combinaison et/ou composition pour induire la différenciation des cardiomyocytes ou neuronale - Google Patents

Procédé amélioré, combinaison et/ou composition pour induire la différenciation des cardiomyocytes ou neuronale Download PDF

Info

Publication number
WO2015119575A3
WO2015119575A3 PCT/SG2015/000032 SG2015000032W WO2015119575A3 WO 2015119575 A3 WO2015119575 A3 WO 2015119575A3 SG 2015000032 W SG2015000032 W SG 2015000032W WO 2015119575 A3 WO2015119575 A3 WO 2015119575A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
combination
improved method
neuronal
differentation
Prior art date
Application number
PCT/SG2015/000032
Other languages
English (en)
Other versions
WO2015119575A2 (fr
Inventor
Se Ngie Winston SHIM
Ashish Mehta
Chrishan JA RAMACHANDRA
En Hou Philip WONG
Original Assignee
Singapore Health Services Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Services Pte Ltd filed Critical Singapore Health Services Pte Ltd
Publication of WO2015119575A2 publication Critical patent/WO2015119575A2/fr
Publication of WO2015119575A3 publication Critical patent/WO2015119575A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé amélioré pour induire la différenciation des cardiomyocytes ou neuronale à l'aide d'une combinaison et/ou d'une composition de facteurs. La présente invention comprend également la combinaison et/ou la composition de facteurs. Par exemple, les facteurs comprennent au moins un inhibiteur de la protéine kinase activée par le mitogène p38 (p38-MAPK); au moins un immunosuppresseur; au moins un modulateur de Wnt; et au moins un modulateur de kinase.
PCT/SG2015/000032 2014-02-06 2015-02-05 Procédé amélioré, combinaison et/ou composition pour induire la différenciation des cardiomyocytes ou neuronale WO2015119575A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG2014010649 2014-02-06
SG2014010649 2014-02-06

Publications (2)

Publication Number Publication Date
WO2015119575A2 WO2015119575A2 (fr) 2015-08-13
WO2015119575A3 true WO2015119575A3 (fr) 2016-06-23

Family

ID=53778578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2015/000032 WO2015119575A2 (fr) 2014-02-06 2015-02-05 Procédé amélioré, combinaison et/ou composition pour induire la différenciation des cardiomyocytes ou neuronale

Country Status (1)

Country Link
WO (1) WO2015119575A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4073235A4 (fr) * 2019-12-09 2024-02-14 Wisconsin Alumni Research Foundation Multiplication in vitro de progéniteurs neuronaux de sous-type dopaminergiques dérivés de cellules souches pluripotentes
JPWO2021251393A1 (fr) * 2020-06-09 2021-12-16

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080187494A1 (en) * 2005-09-12 2008-08-07 Es Cell International Pte Ltd Cardiomyocyte Production
WO2010144696A1 (fr) * 2009-06-11 2010-12-16 Burnham Institute For Medical Research Différenciation dirigée de cellules souches
WO2012067266A1 (fr) * 2010-11-17 2012-05-24 Kyoto University Agent et procédé de prolifération de cardiomyocytes et/ou de cellules progénitrices cardiaques
WO2014025315A1 (fr) * 2012-08-07 2014-02-13 Singapore Health Services Pte Ltd Procédé, combinaison et/ou composition pour induire la différenciation des cardiomyocytes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080187494A1 (en) * 2005-09-12 2008-08-07 Es Cell International Pte Ltd Cardiomyocyte Production
WO2010144696A1 (fr) * 2009-06-11 2010-12-16 Burnham Institute For Medical Research Différenciation dirigée de cellules souches
WO2012067266A1 (fr) * 2010-11-17 2012-05-24 Kyoto University Agent et procédé de prolifération de cardiomyocytes et/ou de cellules progénitrices cardiaques
WO2014025315A1 (fr) * 2012-08-07 2014-02-13 Singapore Health Services Pte Ltd Procédé, combinaison et/ou composition pour induire la différenciation des cardiomyocytes

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BIKKAVILI RK ET AL.: "p38 mitogen-activated protein kmase regulates canonical Wnt- betacatenin signaling by inactivation of GSK3beta.", J CELL SCI., vol. 121, 1 November 2008 (2008-11-01), pages 3598 - 3607 *
BURRIDGE PW ET AL.: "Production of de novo cardiomyocytes:human pluripotent stem cell differentiation and direct reprogramming.", CELL STEM CELL, vol. 10, no. 1, 6 January 2012 (2012-01-06), pages 16 - 28, XP028434719, DOI: doi:10.1016/j.stem.2011.12.013 *
CAI J ET AL.: "BMP and TGF-beta pathway mediators are critical upstream regulators of Wnt signaling during midbrain dopamine differentiation in human pluripotent stem cells.", DEV BIOL., vol. 376, no. 1, 1 April 2013 (2013-04-01), pages 62 - 73, XP028988428, DOI: doi:10.1016/j.ydbio.2013.01.012 *
CHEN A ET AL.: "Considerations in designing systems for large scale production of human cardiomyocytes from pluripotent stem cells.", STEM CELL RES THER., vol. 5, no. 1, 21 January 2014 (2014-01-21), pages 12, XP021208883, DOI: doi:10.1186/scrt401 *
FARNSWORTH SL ET AL.: "Directed neural differentiation of induced pluripotent stem cells from non-human primates.", EXP BIOL MED (MAYWOOD)., vol. 238, no. 3, March 2013 (2013-03-01), pages 276 - 284 *
GAUR M ET AL.: "Timed inhibition of p38MAPK directs accelerated differentiation of human embryonic stem cells into cardiomyocytes.", CYTOTHERAPY., vol. 12, no. 6, October 2010 (2010-10-01), pages 807 - 817, XP055196533, DOI: doi:10.3109/14653249.2010.491821 *
GRAICHEN R ET AL.: "Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK.", DIFFERENTIATION. 2008 APR;, vol. 76, no. 4, 15 November 2007 (2007-11-15), pages 357 - 370, XP026772221, DOI: doi:10.1111/j.1432-0436.2007.00236.x *
HUNT J ET AL.: "Cyclosporin A has direct effects on adult neural precursor cells.", J NEUROSCI., vol. 30, no. 8, 24 February 2010 (2010-02-24), pages 2888 - 2896 *
KUMA Y ET AL.: "BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo.", J BIOL CHEM., vol. 280, no. 20, 20 May 2005 (2005-05-20), pages 19472 - 19479, XP007913553, DOI: doi:10.1074/jbc.M414221200 *
LIAN X ET AL.: "Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling.", PROC NATL ACAD SCI USA., vol. 109, no. 27, 3 July 2012 (2012-07-03), pages E1848 - E1857, XP055053519, DOI: doi:10.1073/pnas.1200250109 *
MA L ET AL.: "Mitogen-activated protein kinase p38 regulates the Wnt/cyclic GMP/Ca2+ non-canonical pathway.", J BIOL CHEM., vol. 282, no. 39, 28 September 2007 (2007-09-28), pages 28980 - 28990, XP055196569, DOI: doi:10.1074/jbc.M702840200 *
SMITH JL ET AL.: "Targeting combinatorial transcriptional complex assembly at specific modules within the interleukin-2 promoter by the immunosuppressant SB203580.", J BIOL CHEM., vol. 278, no. 42, 17 October 2003 (2003-10-17), pages 41034 - 41046, XP055196570, DOI: doi:10.1074/jbc.M305615200 *
UOSAKI H ET AL.: "Identification of chemicals inducing cardiomyocyte proliferation in developmental stage-specific manner with pluripotent stem cells.", CIRC CARDIOVASC GENET. 2013 DEC;, vol. 6, no. 6, pages 624 - 633, XP009177572, DOI: doi:10.1161/CIRCGENETICS.113.000330 *
VARADARAJAN, S: "p38 MAPKs coordinately regulate distinct phases of autophagy and lysosomal biogenesis.", PROQUEST, 2011 *
YAN P ET AL.: "Cyclosporin-A potently induces highly cardiogenic progenitors from embryonic stem cells.", BIOCHEM BIOPHYS RES COMMUN., vol. 379, no. 1, 30 January 2009 (2009-01-30), pages 115 - 120, XP025770136, DOI: doi:10.1016/j.bbrc.2008.12.019 *
ZHU WZ ET AL.: "Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells.", CIRC RES., vol. 107, no. 6, 17 September 2010 (2010-09-17), pages 776 - 786 *

Also Published As

Publication number Publication date
WO2015119575A2 (fr) 2015-08-13

Similar Documents

Publication Publication Date Title
IL282468A (en) 2-Amino-n-heteroaryl-nicotinamides as inhibitors of nav1.8
IL268534A (en) Methods and compounds for gene delivery across the vasculature
ZA202103223B (en) Process for the preparation of (s)-nicotin from myosmine
WO2018089261A3 (fr) Composés et méthodes de modulation de kinase de lymphocytes t inductible par l'interleukine 2
AU2019382117A1 (en) Process for the preparation of (S)-nicotin from myosmine
EP3524042A4 (fr) Facteurs de forme de support modulaire pour plateformes informatiques
WO2017031360A8 (fr) Capture d'acides nucléiques à l'aide d'un système utilisant une nucléase guidée par des acides nucléiques
IL286868A (en) Compounds and methods that monitor the expression of genes in the central nervous system
EP3253798A4 (fr) Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
WO2016061389A3 (fr) Anticorps anti-alpha-synucléine et leurs méthodes d'utilisation
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
WO2018048867A8 (fr) Systèmes et procédés d'actionnement de dispositifs à actionnement hydraulique
EP3893883A4 (fr) Méthodes pour le traitement de la dépression
EP3102207A4 (fr) Inhibiteurs de la caséine kinase 1 à base d'azole 2,4,5-tri-substitué en tant qu'inducteurs de la cardiomyogenèse
EP3471846A4 (fr) Substrat sécurisé pour produits à gratter
EP3185655B8 (fr) Procédé de codage individuel de substrats métal-céramiques
PL3525799T3 (pl) Sposób ustanawiania, przywracania i utrzymywania homeostazy powierzchni oka
WO2016167944A3 (fr) Compositions et méthodes permettant de traiter l'hyperperméabilité intestinale
EP3525805A4 (fr) Compositions et méthodes de modulation du système immunitaire
EP3366817A4 (fr) Substrat de base, procédé de fabrication d'un substrat de base, et procédé de fabrication de cristal de nitrure du groupe 13
EP3756133A4 (fr) Procédé d'authentification d'articles
EP3466952A4 (fr) Nouvel inhibiteur de la kinase flt3 et son utilisation
LT3781401T (lt) Substratų spausdinimo sistema ir spausdinimo sistemos naudojimo būdas
EP3468570A4 (fr) Compositions pour systèmes biologiques et leurs procédés de préparation et d'utilisation
WO2015119575A3 (fr) Procédé amélioré, combinaison et/ou composition pour induire la différenciation des cardiomyocytes ou neuronale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15745978

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15745978

Country of ref document: EP

Kind code of ref document: A2